Typeâ… Cannalinoid Receptor Antgonists In The Treatment Of Typeâ…¡ Diabetes Research

Cannabinoid receptor 1(CB1) is widely distributed in the central n ervous system and peripheral tissue and organs, activation can promote appetite and enhance lipid metabolism, however, inhibited not only ca n obviously reduce the appetite, weight loss, but also can significantly improve the obesity associated with hyperglycemia, insulin resistance a nd lipid metabolism disorder. We through the I cannabinoid receptor an tagonist rimonabant on mice to see experimental treatment, from the se cond week of treatment, food consumption were significantly lower tha n normal control mice, compared to the control group, very significant difference(P<0.001) have been show., reflects the suppression, rimonab ant on mice feeding will appetite obviously reduced. In the subsequent treatment, the treatment group of the animal feed consumption has bee n maintained at a relatively stable level. Because the mice consumed f ood decreased, the corresponding weight, also on the decline. After fou r weeks of treatment, P<0.001 compared to the control group animal,, there was a big difference between the. Description of rimonabant in re ducing animal consumed food at the same time, the slimming effect on obesity mice. Rimonabant on animal treatment a week later, mice fasti ng blood glucose levels rapidly decreased and reduced to a reasonable level, compared to the control group animals there have been very sign ificant difference can be found(P<0.001), and then three weeks of trea tment, mice blood sugar stable and in a reasonable range. Explain it to the obese mice blood glucose can significantly improve. In the glucos e tolerance test, two groups of animal were present in 15~30 minutes p eak, but with the passage of time, blood sugar drop slowly, to 120 min utes, the treatment group of animal blood sugar back to normal, while the control group animal blood sugar is still maintained at a relatively high level. The impaired fasting glucose tolerance in obese mice, while the rimonabant treatment, improve the glucose tolerance. AUC display,as the value of treatment group and control group: 1623 of the value: 2118, the remarkable difference. The treatment group of the animal by rimonabant after four weeks of treatment, insulin resistance, triglyceride levels also decreased, compared with the control group, P value <0.001. That rimonabant by weight loss, to lowering blood glucose, improve obesity associated with hyperglycemia, insulin resistance and lipid met abolism disorder effect. Study of rimonabant hypoglycemic, improveme nt of obesity associated with hyperglycemia, insulin resistance and lipidmetabolism disorder, is conducive to our development on the weight l oss drug to provide ideas, diabetes type II(T2DM) to provide new ide as and new methods of treatment.